HDAC Assay Buffer 5X (Biotechnology Grade)

<strong>HDAC Assay Buffer 5X </strong>_x000D_ <strong>Catalog number:</strong> B2010129_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Volume/Weight:</strong> 10 mL_x000D_ <strong>pH:</strong> 8_x000D_ <strong>Supplied as:</strong> 5X Concentrate (Dilute 1:5 before use)_x000D_ <strong>Appearance:</strong> Clear solution_x000D_ <strong>Applications:</strong> optimized buffer for Histone Deacetylase Assays (HDAC)._x000D_ <strong>Storage:</strong> −20°C_x000D_ <strong>Keywords:</strong> HDAC buffer, hdac assay buffer, hdac activity assay buffer_x000D_ <strong>Grade:</strong> Biotechnology grade. All components are highly pure (minimum 99%). All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered on a 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Yoon S, Eom GH. HDAC and HDAC Inhibitor: From Cancer to Cardiovascular_x000D_ Diseases. Chonnam Med J. 2016 Jan;52(1):1-11._x000D_ _x000D_ 2: Hull EE, Montgomery MR, Leyva KJ. HDAC Inhibitors as Epigenetic Regulators of_x000D_ the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases. Biomed_x000D_ Res Int. 2016;2016:8797206._x000D_ _x000D_ 3: Booth L, Roberts JL, Poklepovic A, Kirkwood J, Dent P. HDAC inhibitors_x000D_ enhance the immunotherapy response of melanoma cells. Oncotarget. 2017 May_x000D_ 17;8(47):83155-83170._x000D_ _x000D_ 4: Schobert R, Biersack B. Multimodal HDAC Inhibitors with Improved Anticancer_x000D_ Activity. Curr Cancer Drug Targets. 2018;18(1):39-56._x000D_ _x000D_ 5: Lyu X, Hu M, Peng J, Zhang X, Sanders YY. HDAC inhibitors as antifibrotic_x000D_ drugs in cardiac and pulmonary fibrosis. Ther Adv Chronic Dis. 2019 Jul_x000D_ 18;10:2040622319862697._x000D_ _x000D_ 6: Lu H, Bai L, Zhou Y, Lu Y, Jiang Z, Shi J. Recent Study of Dual HDAC/PARP_x000D_ Inhibitor for the Treatment of Tumor. Curr Top Med Chem. 2019;19(12):1041-1050._x000D_ _x000D_ 7: Hesham HM, Lasheen DS, Abouzid KAM. Chimeric HDAC inhibitors: Comprehensive_x000D_ review on the HDAC-based strategies developed to combat cancer. Med Res Rev._x000D_ 2018 Sep;38(6):2058-2109._x000D_ _x000D_ 8: Li Y, Wang F, Chen X, Wang J, Zhao Y, Li Y, He B. Zinc-dependent Deacetylase_x000D_ (HDAC) Inhibitors with Different Zinc Binding Groups. Curr Top Med Chem._x000D_ 2019;19(3):223-241._x000D_ _x000D_ 9: Kim T, Song S, Park Y, Kang S, Seo H. HDAC Inhibition by Valproic Acid_x000D_ Induces Neuroprotection and Improvement of PD-like Behaviors in LRRK2 R1441G_x000D_ Transgenic Mice. Exp Neurobiol. 2019 Aug 31;28(4):504-515._x000D_ _x000D_ 10: Amin SA, Adhikari N, Jha T. Is dual inhibition of metalloenzymes HDAC-8 and_x000D_ MMP-2 a potential pharmacological target to combat hematological malignancies?_x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/28501516/">Pharmacol Res</a>. 2017 Aug;122:8-19._x000D_ _x000D_ <strong>Products Related to HDAC Assay Buffer 5X </strong> <a>Biochemical Buffers and Solutions</a>